<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04240262</url>
  </required_header>
  <id_info>
    <org_study_id>MYOMIC2</org_study_id>
    <nct_id>NCT04240262</nct_id>
  </id_info>
  <brief_title>Microwave Ablation for Leiomyoma</brief_title>
  <acronym>MYOMIC2</acronym>
  <official_title>Prospective Observational Trial of Microwave Ablation for Leiomyoma (MYOMIC2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective observational study aims to evaluate the effectiveness and acceptability of
      percutaneous or vaginal ultrasound guided microwave ablation for the treatment of symptoms
      related to uterine fibroids. We will include 200 women.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Symptom severity of uterine fibroids</measure>
    <time_frame>6 months post treatment</time_frame>
    <description>Score of validated form Uterine Fibroid symptom- Quality of Life questionnaire. minumum 0, maximum 100 where higher scores indicate higher symptom severity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life score</measure>
    <time_frame>6 months post treatment</time_frame>
    <description>Score of validated form Uterine Fibroid symptom- Quality of Life questionnaire.minumum 0, maximum 100 where higher scores indicate higher quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>menstrual bleeding</measure>
    <time_frame>6 months post treatment</time_frame>
    <description>Score on validated Pictorial Bleeding assessment chart. minimum 1, no maximum. higher scores indicate more bleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acceptability</measure>
    <time_frame>2 hours post treatment and 6 months post treatment (+/- 2 weeks)</time_frame>
    <description>Answer to question: if you were to recommend the treatment to a friend on a scale from 1-7 where 7 is the highest rating- what would you say.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Uterine Fibroid</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Women with symptoms from uterine fibroids
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  premenopausal

          -  no future child wish

          -  acceptable risks for general anestesia or sedation

          -  willing to comply with protocol

        Exclusion Criteria:

          -  current or future child wish

          -  bleeding disorder with increased risk of bleeding
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Helena Kopp Kallner</name>
      <address>
        <city>Taby</city>
        <zip>18352</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena K Kallner, MD</last_name>
      <phone>+46704402070</phone>
      <email>helena.kopp-kallner@ki.se</email>
    </contact>
    <investigator>
      <last_name>Helena Kopp Kallner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 20, 2020</study_first_submitted>
  <study_first_submitted_qc>January 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>March 5, 2020</last_update_submitted>
  <last_update_submitted_qc>March 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Helena Kopp Kallner</investigator_full_name>
    <investigator_title>Senior consultant ob/gyn</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

